Latest Corporate News

PHARMASCIENCE CANADA LAUNCHES (PR)PMS-OLMESARTAN


An estimated 7.5 million Canadians live with hypertension1. Severe headaches, fatigue or confusion and even vision problems are symptoms of hypertension2.

With our recent launch of Prpms-OLMESARTAN, a generic bioequivalent to PrOlmetec®, Pharmascience Canada is showing its commitment to help Canadians living with hypertension. Prpms-OLMESARTAN is an angiotensin II AT1 receptor blocker indicated for the treatment of mild to moderate essential hypertension3 and is available in 20 mg and 40 mg formats4.

Important statistics regarding hypertension5:

  • About one (1) in five (5) adults live with hypertension;
  • Approximately one (1) in five (5) adults with hypertension are unaware of their condition;
  • Despite recent achievements, one (1) in three (3) people with hypertension have uncontrolled blood pressure;
  • Patients living with diabetes and kidney disease are considered as high-risk candidates for hypertension.

Early detection of high blood pressure and its management can improve the lives of patients living with hypertension6. Pharmascience is proud to help patients living with this condition through offering a new treatment option.

 

PrOlmetec® is a registered trademark of Daiichi Sankyo Company, Limited, used under license and distributed by Merck Canada Inc.


2. Ibid

4. Ibid

6. Ibid



Back to News